Abstract
Cytomegalovirus (CMV) is the most important of the 8 presently-recognized human herpes viruses in terms of its pathogenic potential in immunocompromised hosts. CMV is responsible for substantial morbidity after solid organ and bone marrow transplantation [1,2] and is the most common cause of ‘opportunistic’ viral disease in HIV/AIDS [3]. Prevention and treatment of CMV disease is clearly a high priority.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Peterson PK, Balfour HH Jr, Fryd DS, Ferguson RM, Simmons RL. Fever in renal transplant recipients: causes, prognostic significance and changing patterns at the University of Minnesota Hospital. Am. J. Med. 1981; 71: 345–351.
Neiman PE, Reeves W, Ray G et al. A prospective analysis of interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J. Infect. Dis. 1977; 136: 754–767.
Selik RM, Chu S Y, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann. Intern. Med. 1995; 123: 933–936.
Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995; 333: 1038–1044.
Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343: 749–753.
Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 1989; 320: 1381–1387.
Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358: 162–164.
Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyer JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 1993; 118: 173–178.
Spector SA, McKinley GF, Lalezari JP et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N. Engl. J. Med. 1996; 334: 1491–1497.
Weller S, Blum MR, Doucette M et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 1993; 54: 595–605.
Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: a randomized trial. Ann. Intern. Med. 1994; 120: 375–381.
Bowen EF, Wilson P, Atkins M et al. Natural history of untreated cytomegalovirus retinitis. Lancet 1995; 346: 1671–1673.
Freitas VR, Fraser-Smith EB, Matthews TR et al. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res. 1989; 112: 205–212.
Manischewitz JF, Quinnan GV, Lane HC et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 1990; 34: 373–375.
Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch. Opthalmol. 1996; 114: 23–32.
Lopez C, Simmons RL, Mauer SM, Najarian JS, Good RA, Gentry S. Association of renal allograft rejection with virus infections. Am. J. Med. 1974; 56: 280–289.
Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus infection — an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55: 851–857.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Balfour, H.H. (1997). Prevention and treatment of cytomegalovirus (CMV) disease. In: Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Late Graft Loss. Transplantation and Clinical Immunology, vol 28. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5434-5_21
Download citation
DOI: https://doi.org/10.1007/978-94-011-5434-5_21
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6286-2
Online ISBN: 978-94-011-5434-5
eBook Packages: Springer Book Archive